Sputnik Light: Difference between revisions
CSV import |
CSV import |
||
| Line 37: | Line 37: | ||
{{Viral vector COVID-19 vaccines}} | {{Viral vector COVID-19 vaccines}} | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
{{No image}} | |||
Revision as of 23:36, 10 February 2025
Sputnik Light is a single-dose COVID-19 vaccine developed by the Gamaleya Research Institute of Epidemiology and Microbiology in Russia. It is a variant of the two-dose Sputnik V vaccine, which was the first registered COVID-19 vaccine in the world.
Overview
Sputnik Light is a viral vector vaccine that uses a modified version of the common cold-causing adenovirus to deliver a piece of the SARS-CoV-2 virus's spike protein to cells in the body. This triggers an immune response, which helps protect against future infection.
Efficacy
According to the developers, Sputnik Light has an efficacy rate of around 80%, based on data from Russia's mass vaccination program. However, these results have not been peer-reviewed. The vaccine is said to provide immunity within 3-4 weeks of administration.
Approval and Distribution
As of September 2021, Sputnik Light has been approved for emergency use in several countries, including Russia and Argentina. It is also under review by the World Health Organization (WHO) for emergency use listing.
Side Effects
Common side effects of Sputnik Light include pain at the injection site, fever, fatigue, headache, muscle pain, and chills. These are similar to the side effects reported for other COVID-19 vaccines.
See Also
- COVID-19 pandemic
- COVID-19 vaccines
- Sputnik V
- Gamaleya Research Institute of Epidemiology and Microbiology
References
<references />
| Viral vector COVID-19 vaccines | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This COVID-19 vaccine related article is a stub.
|
